Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression
Thorsten Mikoteit, Johannes Beck, Anne Eckert, et al.
Psychopharmacology (2014) Vol. 231, Iss. 15, pp. 2955-2965
Closed Access | Times Cited: 62

Showing 26-50 of 62 citing articles:

BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients
Elisabetta Maffioletti, Massimo Gennarelli, Giulio Gainelli, et al.
Journal of Ect (2019) Vol. 35, Iss. 3, pp. 189-194
Closed Access | Times Cited: 30
The association of brain-derived neurotrophic factor with the diagnosis and treatment response in depression
Matea Nikolac Perković, Martin Gredičak, Marina Šagud, et al.
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 4, pp. 283-296
Closed Access | Times Cited: 10
Serum brain-derived neurotrophic factor, Val66Met polymorphism and open-label SSRI treatment response in Major Depressive Disorder
A. J. Smit, Gwyneth W. Y. Wu, Ryan Rampersaud, et al.
Psychoneuroendocrinology (2024) Vol. 165, pp. 107045-107045
Open Access | Times Cited: 3
Electroconvulsive therapy improves clinical manifestations of treatment-resistant depression without changing serum BDNF levels
Chiara Rapinesi, Georgios D. Kotzalidis, Martina Curto, et al.
Psychiatry Research (2015) Vol. 227, Iss. 2-3, pp. 171-178
Closed Access | Times Cited: 31
Daily fluctuation of emotions and memories thereof: Design and methods of an experience sampling study of major depression, social phobia, and controls
Andrew T. Gloster, Marcel Miché, Hanna Wersebe, et al.
International Journal of Methods in Psychiatric Research (2017) Vol. 26, Iss. 3
Open Access | Times Cited: 29
Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future
Elisabetta Maffioletti, Rosana Carvalho Silva, Marco Bortolomasi, et al.
Brain Sciences (2021) Vol. 11, Iss. 9, pp. 1120-1120
Open Access | Times Cited: 22
The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression
Reiji Yoshimura, Naomichi Okamoto, Enkhmurun Chibaatar, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 584-584
Open Access | Times Cited: 8
Role of Serum Brain Derived Neurotrophic Factor and Central N-Acetylaspartate for Clinical Response under Antidepressive Pharmacotherapy
Sarah Nase, Stephan Köhler, Jacqueline Jennebach, et al.
Neurosignals (2016), pp. 1-14
Open Access | Times Cited: 25
Remission of depression following electroconvulsive therapy (ECT) is associated with higher levels of brain-derived neurotrophic factor ( BDNF)
Thiago Fernando Vasconcelos Freire, Marcelo Pio de Almeida Fleck, Neusa Sica da Rocha
Brain Research Bulletin (2016) Vol. 121, pp. 263-269
Open Access | Times Cited: 25
Association of serum BDNF level and Val66Met polymorphism with response to treatment in patients of major depressive disease: A step towards personalized therapy
Piyush Pathak, Aseem Mehra, Sant Ram, et al.
Behavioural Brain Research (2022) Vol. 430, pp. 113931-113931
Closed Access | Times Cited: 13
The BDNF Val66Met polymorphism is associated with escitalopram response in depressed patients
Wissam El‐Hage, Patrick Vourc’h, Philippe Gaillard, et al.
Psychopharmacology (2014) Vol. 232, Iss. 3, pp. 575-581
Closed Access | Times Cited: 23
Alterations in Serum BDNF and GDNF Levels after 12 Weeks of Antidepressant Treatment in Female Outpatients with Major Depressive Disorder
Young‐Min Park, Bun-Hee Lee
Psychiatry Investigation (2018) Vol. 15, Iss. 8, pp. 818-823
Open Access | Times Cited: 22
Repetitive enhancement of serum BDNF subsequent to continuation ECT
Thomas Vanicek, Georg S. Kranz, Benjamin Vyssoki, et al.
Acta Psychiatrica Scandinavica (2019) Vol. 140, Iss. 5, pp. 426-434
Open Access | Times Cited: 22
Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence
Helena Domin, Bernadeta Szewczyk, Bartłomiej Pochwat, et al.
Psychopharmacology (2016) Vol. 234, Iss. 4, pp. 631-645
Open Access | Times Cited: 20
The Comparison of Effectiveness of Various Potential Predictors of Response to Treatment With SSRIs in Patients With Depressive Disorder
Martin Bareš, Tomáš Novák, Martin Brunovský, et al.
The Journal of Nervous and Mental Disease (2016) Vol. 205, Iss. 8, pp. 618-626
Closed Access | Times Cited: 18
Effect of electroconvulsive therapy on brain‐derived neurotrophic factor levels in patients with major depressive disorder
Annamari Sorri, Kaija Järventausta, Olli Kampman, et al.
Brain and Behavior (2018) Vol. 8, Iss. 11
Open Access | Times Cited: 18
Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder
Wei Zheng, Li-Mei Gu, Yanling Zhou, et al.
Current Neuropharmacology (2022) Vol. 21, Iss. 4, pp. 1013-1021
Open Access | Times Cited: 9
Early change of prefrontal theta cordance and occipital alpha asymmetry in the prediction of responses to antidepressants
Martin Bareš, Tomáš Novák, Přemysl Vlček, et al.
International Journal of Psychophysiology (2019) Vol. 143, pp. 1-8
Closed Access | Times Cited: 14
Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways
Andrzej Wróbel, Anna Serefko, Andrzej Woźniak, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 189, pp. 172842-172842
Open Access | Times Cited: 14
Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder
Shoko Kagawa, Kazuo Mihara, Takeshi Suzuki, et al.
Neuropsychobiology (2017) Vol. 75, Iss. 3, pp. 145-150
Closed Access | Times Cited: 14
Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial
Céline K. Stäuble, Markus L. Lampert, Samuel Allemann, et al.
Trials (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 11
The Clinician Scientist Training Program in Iran: Catalyzing Clinical Science Advancements
Sophia Esalatmanesh, Ladan Kashani, Shahin Akhondzadeh
Avicenna Journal of Medical Biotechnology (2023)
Open Access | Times Cited: 4
The researcher's guide to selecting biomarkers in mental health studies
Josine E. Verhoeven, Owen M. Wolkowitz, Isaac Barr Satz, et al.
BioEssays (2024) Vol. 46, Iss. 10
Open Access | Times Cited: 1
Precision Medicine in Depression: The Role of Proteomics and Metabolomics in Personalized Treatment Approaches
Mohamad Jaber, Hamza Kahwaji, S Nasr, et al.
Advances in experimental medicine and biology (2024), pp. 359-378
Closed Access | Times Cited: 1
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
Martin A. Katzman, Andrew A. Nierenberg, Dalia Wajsbrot, et al.
Journal of Clinical Psychopharmacology (2017) Vol. 37, Iss. 5, pp. 555-561
Open Access | Times Cited: 10

Scroll to top